News

HLI & AMRA partner to provide advanced body composition profiling

Amy Schofield 11 January 2018

AMRA, the international leader in body composition analysis, and Human Longevity, Inc. (HLI), the genomics-powered health intelligence company, have announced a new agreement that will see AMRA’s body composition profiling added to HLI’s premier health assessment, the Health Nucleus experience.
 
The Health Nucleus integrates genomics, metabolic profiling and other clinical testing with advanced whole body and brain magnetic resonance imaging (MRI), which now includes the body composition profiling provided by AMRA. This integrated, whole-body experience empowers patients to take control of their own health by proactively planning to stay ahead of aging and illness.
 
AMRA’s mission is to establish a new global standard in body composition assessment and to confront global health challenges by enhancing the evidence base needed to predict and prevent disease in a precise, cost-effective way to understand our bodies far beyond what is commonly used today.

AMRA is the first company in the world to transform images from a six minute whole body MRI into 3D-volumetric fat and muscle measurements, while enabling market-leading accuracy and precision when assessing fat and muscle volume and distribution, as well as metabolic status.
 
J. Craig Venter, HLI’s CEO, said: “While we have been piloting AMRA’s body composition profiling for over a year, we are excited to now offer their unique modality to all our Health Nucleus clients. We believe this will provide an additional and valuable layer of powerful insight into a person’s metabolic status.”
 
Tommy Johansson, Chief Executive Officer of AMRA, said: “We hope that our body composition profiling, combined with HLI’s cutting-edge digital health assessments, will set the standard for the future of personalised healthcare.”

 

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.